Home/Pipeline/Biosimilar Development

Biosimilar Development

Immunology / Oncology

Early DevelopmentExploratory

Key Facts

Indication
Immunology / Oncology
Phase
Early Development
Status
Exploratory
Company

About Bora Pharmaceuticals

Bora Pharmaceuticals has established itself as a premier hybrid CDMO and pharmaceutical developer in Asia, achieving significant scale with a market capitalization exceeding $57 billion. The company's strategy successfully integrates high-margin contract services with proprietary drug development, creating a diversified and resilient revenue model. Its core achievements include building PIC/S and FDA-compliant manufacturing facilities, developing a robust pipeline of complex generics and specialty products, and securing a strong position as a critical supply chain partner for multinational pharmaceutical companies.

View full company profile

Other Immunology / Oncology Drugs

DrugCompanyPhase
BHV-1300BiohavenPhase 1/2
BHV-1100BiohavenPhase 1